Plus Therapeutics, Inc. (NASDAQ:PSTV) Director Purchases $13,020.00 in Stock

Plus Therapeutics, Inc. (NASDAQ:PSTV) Director Robert P. Lenk acquired 7,000 shares of the company’s stock in a transaction dated Monday, September 13th. The shares were bought at an average cost of $1.86 per share, with a total value of $13,020.00. Following the purchase, the director now owns 10,000 shares in the company, valued at $18,600. The purchase was disclosed in a legal filing with the SEC, which is available through this link.

PSTV traded down $0.02 during trading on Wednesday, hitting $1.83. 1,134 shares of the company’s stock were exchanged, compared to its average volume of 1,204,817. Plus Therapeutics, Inc. has a 1 year low of $1.79 and a 1 year high of $5.42. The stock has a 50 day moving average price of $2.04 and a 200 day moving average price of $2.32. The firm has a market cap of $22.12 million, a P/E ratio of -1.09 and a beta of 0.37.

Plus Therapeutics (NASDAQ:PSTV) last posted its earnings results on Thursday, July 22nd. The company reported ($0.25) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.02). During the same quarter last year, the business posted ($0.45) EPS. Sell-side analysts forecast that Plus Therapeutics, Inc. will post -0.98 earnings per share for the current year.

Institutional investors and hedge funds have recently modified their holdings of the business. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Plus Therapeutics in the second quarter valued at about $33,000. Renaissance Technologies LLC acquired a new position in Plus Therapeutics during the 2nd quarter worth approximately $45,000. State Street Corp purchased a new position in Plus Therapeutics in the 2nd quarter worth approximately $88,000. Northern Trust Corp acquired a new stake in Plus Therapeutics in the second quarter valued at approximately $104,000. Finally, Citadel Advisors LLC purchased a new stake in shares of Plus Therapeutics during the second quarter valued at approximately $111,000. Institutional investors own 12.68% of the company’s stock.

A number of equities analysts have weighed in on the stock. Maxim Group started coverage on shares of Plus Therapeutics in a report on Friday, July 23rd. They issued a “buy” rating and a $6.00 price target on the stock. HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of Plus Therapeutics in a report on Friday, July 23rd. Finally, Zacks Investment Research downgraded Plus Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, September 9th.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium NanoLiposomes, a patented radiotherapy for patients with recurrent glioblastoma, which is in the Phase 1 dose-finding clinical trial.

Featured Article: Dividend Yield

Insider Buying and Selling by Quarter for Plus Therapeutics (NASDAQ:PSTV)

Receive News & Ratings for Plus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Plus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.